Horizon's Poor Primary Care Performance Overshadows River Vision Buy
Horizon's deal to buy River Vision to bolster its orphan product pipeline is cast into the shade by a disappointing first quarter performance for its primary care business.
You may also be interested in...
Horizon CEO says safety trial will be conducted in a larger patient population following discussions during the US FDA advisory committee meeting.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.
FDA seems poised to approve the drug for the orphan eye disease called TED, but remains concerned about labeling for some adverse events.